Advanced Filters
noise
Found 1,843 clinical trials
J Jie He, Dr.

Neoadjuvant Treatment Real-world Clinical Outcomes in NSCLC

Despite the clinical success of immune checkpoint blockade (ICB), in neoadjuvant setting, there is still a lack of valid data for operable NSCLC in the real world. This study aim to compare the clinical outcomes (pathologic response rate versus survival) of neoadjuvant immunochemotherapy with neoadjuvant chemotherapy in the real world, …

18 - 85 years of age All Phase N/A
J Jhingook Kim, MD

Cell Free DNA for the Diagnosis and Treatment in Early NSCLC

The aim of the study is to evaluate whether peripheral circulating cell-free tumor DNA (cfDNA) can aid screening of recurrence after complete resection of early stage non-small cell lung cancer.

18 - 90 years of age All Phase N/A
K Kimberly Wendt

GEMINI-NSCLC: NSCLC Biomarker Study

Non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care therapy and disease surveillance.

18 years of age All Phase N/A
Q Qu Liudi

A Prospective, Multicenter, Non-interventional, Real-world Study to Characterize Changes in Molecular Markers After Three Weeks of Targeted Therapy With Oxitinib in EGFRm NSCLC

To evaluate the characteristics of genetic variationmutations at baseline and 3 weeks after oxitinib treatment in EGFRm NSCLC

18 years of age All Phase N/A

A Study to Describe the Diagnostic and Therapeutic Path of Patients with NSCLC in Early Stage and Locally Advanced

This is a non-interventional, retrospective observational study to improve knowledge regarding the diagnosis and treatments of patients who have/had non-small cell lung cancer (NSCLC), either early stage (stage I-II).

18 years of age All Phase N/A
S Shugeng Gao, MD

Real-world Clinical Outcomes of NSCLC Patients Receiving Neoadjuvant Immunotherapy

The goal of this observational study is to evaluate the efficacy and long-term clinical outcomes of different neoadjuvant immunotherapies in non-small cell lung cancer (NSCLC) patients using the real-world data. The main questions it aims to answer are: What the best setting for immune checkpoint inhibitors as the neoadjuvant treatment? …

18 - 85 years of age All Phase N/A

EMPATHY NSCLC: European Registry for Plasma-Based Molecular Profiling in Advanced NSCLC Patients

The goal of this registry is to capture real-world data from plasma- and tissue-based molecular profiling, treatments, outcomes and patient-reported outcomes from patients with advanced or metastatic non-small cell lung cancer (NSCLC). The main objective of the study is to better understand the real-world clinical practice of the use and …

18 years of age All Phase N/A
Y Yuqing Lou

DREAM Study: DNA/RNA-NGS Co-Testing in Driver-Negative, Treatment-Resistant NSCLC

The study is divided into two parts, Part A and Part B. The purpose of Part A is to reveal the proportion of NSCLC patients who are primarily resistant to first-line non-targeted therapy due to the omission of driver genes (especially fusion variations) by DNA-NGS, the median PFS of patients …

years of age All Phase N/A
C Carmmen Garcia

UNC Pleural Fluid Registry

Research with biospecimens such as blood, tissue, or body fluids can help researchers understand how the human body works. Researchers can make new tests to find diseases, understand how treatments work, or find new ways to treat a disease. The purpose of this study is to collect biospecimens for research …

18 years of age All Phase N/A
P Peggy Fitzpatrick, RN

Immunobiology Blood and Tissue Collection of Upper Aerodigestive Malignancies

This research is being done to collect and store biological specimens (biospecimens) from people with cancer, regardless of tumor type, who are receiving treatments known or thought to have an effect on the immune system. The goal of this discovery and exploratory study is to: Understand changes in the immune …

18 years of age All Phase N/A

Simplify language using AI